Pharmacokinetics of Heparin^[*]

 

^* Presented at the Symposium on Heparin, Basel, Switzerland, September, 1974.

• References

• 1 Adolph E. R. Quantitative relations in the physiological constitutions of mammals. Science 1949; 109: 579.
• 2 Benaoerraf B, Miesoher P. Bacterial phagocytosis by the reticuloendothelial system in vivo under different immune conditions. Annals of the New York Academy of Sciences 1960; 88: 184.
• 3 Blakeley J. A. A rapid bedside method for the control of heparin therapy. Canadian Medical Association Journal 1968; 99: 1072.
• 4 Eiber H. B, Danishefsky I, Borelli F. Studies made with radioactive heparin in humans. Angiology 1960; 11: 40.
• 5 Estes J. W. (Letter to the editor) New England Journal of Medicine. 1968; 279: 887
• 6 Estes J. W, Pelikan E. W, Kruger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clinical Pharmacology and Therapeutics 1969; 10: 329.
• 7 Estes J. W. Kinetics of the anticoagulant effect of heparin. Journal of the American Medical Association 1970; a 212: 1492.
• 8 Estes J. W. (Letter to the editor) Journal of the American Medical Association. 214 1970; b 1122
• 9 Estes J. W, Pelikan E. W. Dose and effect metameters in clinical use of heparin. Pharmacologist 1971; 13: 317.
• 10 Estes J. W. The heterogeneity of the anticoagulant response to heparin. Journal of Clinical Pathology 1972; 25: 45.
• 11 Hoch H, Chanutin A. Effects of anticoagulants on serum and plasma. Journal of Biological Chemistry 1952; 197: 503.
• 12 Jaques L. B, Bell H. J. Determination of heparin. Methods of Biochemical Analysis 1951; 7: 253.
• 13 Kruger-Thiemer E. Formal theory of drug dosage regimens. Journal of Theoretical Biology 1966; 13: 212.
• 14 Kruger-Thiemer E. Pharmacokinetics and dose-concentration relationships. In: Physico-Chemical Aspects of Drug Actions: 63. Pergamon Press; New York.: 1968
• 15 Levy G. Kinetics of pharmacologic effects. Clinical Pharmacology and Therapeutics 1966; 7: 362.
• 16 McGovern J. J, Bunker J. P, Goldstein R, Estes J. W. Effect of conjugated estrogens on the coagulation mechanism. Journal of the American Medical Association 1961; 175: 1011.
• 17 Monkhouse F. C. Physiological factors concerned with the removal of injected heparin from the circulating blood. American Journal of Physiology 1954; 178: 223.
• 18 Newman E. V, Bordley J, Winternitz J. The interrelationships of glomerular filtration rate (mannitol clearance), extracellular fluid volume, surface area of the body and plasma concentration of mannitol. Bulletin of the John Hopkins Hospital 1944; 75: 253.
• 19 Olsson P, Lagergren H, Eκ S. The elimination from plasma of intravenous heparin. Acta Medica Scandinavica 1963; 173: 619.
• 20 Padawer J. Conference on Mast Cells and Basophils. Annals of the New York Academy of Sciences 103: 1-492. passim. 1963;
• 21 Rodman Jr. N. F, Barrow E. M, Graham J. B. Diagnosis and control of the hemophiloid states with the partial thromboplastin time (PTT) test. American Journal of Clinical Pathology 1958; 29: 525.
• 22 Rosenberg R. D, Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. Journal of Biological Chemistry 1973; 248: 6490.
• 23 Siegelman A. M, Carlson A. S, Robertson T. Investigation of serum trypsin and related substances. Archives of Biochemistry and Biophysics 1962; 97: 159.
• 24 Spector I, Corn M. Control of heparin therapy with activated partial thromboplastin times. Journal of the American Medical Association 1967; 201: 157.
• 25 Yin E. T, Wessler S, Stoll P. J. Biological properties of the naturally occuring plasma inhibitor to activated factor X. Journal of Biological Chemistry 1971; 246: 3703.